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Trypanosoma cruzi is a protozoan parasite that causes Chagas disease (CD). CD is a persistent, 38 
life-long infection affecting many organs, most notably the heart where it may result in acute 39 
myocarditis and chronic cardiomyopathy. The pathological features include myocardial 40 
inflammation and fibrosis. In the Brazil-strain infected CD-1 mouse that recapitulates many of 41 
the features of human infection, we found increased plasma levels of resolvin D1 (RvD1), a 42 
specialized pro-resolving mediator of inflammation, both during the acute and chronic phases of 43 
the infection (>100 days post infection) as determined by ELISA. Additionally, ELISA on 44 
lysates of trypomastigotes of both the Tuliahan and Brazil strains revealed elevated levels of 45 
RvD1 when compared with lysates of cultured epimastigotes of T. cruzi, tachyzoites of 46 
Toxoplasma gondii, and trypomastigotes of T. brucei, cultured L6E9 myoblasts and culture media 47 
containing no cells.  Lysates of T. cruzi –infected myoblasts also displayed increased levels of 48 
RvD1. Lipid mediator metabolomics confirmed that the trypomastigotes of T. cruzi produced 49 
RvD1, RvD5 and RvE2, which have been demonstrated to modulate the host response to 50 
bacterial infections. Plasma levels of RvD1 maybe both host and parasite derived. Since T. cruzi 51 
synthesizes specialized pro-resolving mediators of inflammation as well as pro-inflammatory 52 
eicosanoids, such as thromboxane A2, one may speculate that by using these lipid mediators to 53 
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List of Abbreviations: 60 
ELISA, Enzyme Linked ImmunoSobrant Assay; FFA, free fatty acid; AA, arachidonic acid; 61 
DHA, docosahexenoic acid; EPA, eicosapentaenoic acid; HDHA, hydroxyl-docosahexenoic 62 
acid; HETE, hydroxy-eicosatetraenoic acid; HEPE, hydroxy-eicosapentaenoic acid; PG, 63 
prostaglandin; TXA2, thromboxane A2; TP, Receptor for TXA2; FP, receptor for PGF2; LT, 64 
leukotriene; LX, lipoxin; SPM, specialized pro-resolving mediator; RvD, resolvins derived from 65 
DHA;  RvE, resolvins derived from EPA; PD, protectin; MaR, maresin; EFA, essential fatty 66 
acid; LO, lipoxygenase; IFN-γ, interferon -; PBMC, peripheral blood mononuclear cell; H&E, 67 
Hematoxylin and Eosin; MRI, magnetic resonance imaging; ECG, electrocardiogram; LM, lipid 68 
metabolite; LC, Liquid chromatography; MS, mass spectrometry; dpi, days post-inoculation; 69 
NDGA, nordihydroguaiaretic acid; TcOYE, T. cruzi old yellow enzyme; TbPGFS, T. brucei 70 
PGF2 synthase.  71 
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The parasite Trypanosoma cruzi is the etiologic agent of Chagas disease. It is endemic in 73 
Mexico, Central and South America where millions of persons are infected or at risk (1).  In 74 
recent years, due to migration of individuals from endemic areas, there has been increased 75 
recognition of Chagas disease in the United States, Europe and other non-endemic areas (2-4). 76 
Additionally, vector transmission of this parasite has been documented in the United States (5). 77 
Although any nucleated cell in the body can be infected, the cardiovascular system is among the 78 
organs targeted by this parasite causing acute myocarditis and chronic cardiomyopathy. 79 
Acute infection with T. cruzi results in an intense inflammatory response associated with an 80 
increased expression of pro-inflammatory mediators including cytokines, chemokines and 81 
endothelin-1(6). We have also previously described the release of the bioactive lipid mediators 82 
prostaglandin F2 (PGF2) and thromboxane A2 (TXA2) from T. cruzi, although TXA2 is 83 
preferentially synthesized (7). TXA2 is a pro-inflammatory, vasoconstrictor with pro-thrombotic 84 
activity through enhanced platelet activation-aggregation.  PGF2 is a pro-inflammatory 85 
vasoconstrictor substance like TXA2 (8); however, it opposes platelet activation by TXA2 and 86 
platelet activating factor (9). Both receptors (TP and FP) couple to Gq and G13, activate the 87 
small GTPase Rho, and promote cellular activation; however, FP expression on leukocytes is not 88 
well documented suggesting the effects of FP on inflammation are likely indirect while the 89 
effects of TP are direct (8).  A previous report indicates that TP can be activated by PGF2 (10), 90 
suggesting a single focal point for the action of pro-inflammatory prostaglandins in Chagas 91 
disease and re-enforcing the prominence of TP to the pathogenesis of disease. 92 
Acute inflammation is a natural host protective mechanism mounted by the body in response to 93 
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injury or invading pathogens. When self-limited, it restores homeostasis (11); however, if left 94 
uncontrolled, excessive inflammation can lead to chronic tissue damage (12). Resolution of 95 
inflammation is an active process orchestrated by a genus of potent molecules known as 96 
specialized pro-resolving mediators (SPM)(13) . SPM, that include the resolvins, protectins and 97 
maresins, are bioactive autacoids with both anti-inflammatory and pro-resolving properties. They 98 
are enzymatically produced from essential fatty acids (EFA), with distinct stereochemistries. 99 
RvD1 biosynthesis involves sequential oxygenations of DHA by 15-lipoxygenase (LO) and 5-100 
LO (14). Using a total organic synthetic approach the complete stereochemistry of RvD1 has 101 
been established as 7S,8R,17S-trihydroxy- 4Z,9E,11E,13Z,15E,19Z-docosahexaenoic acid (15). 102 
RvD1 displays potent leukocyte-directed actions in pico-nanogram concentration range in vivo 103 
(14). In E. coli-induced peritonitis, RvD1 reduces bacterial titers and hypothermia, increases 104 
survival and enhances microbial containment and killing by phagocytes (16). The aspirin 105 
triggered epimer of RvD1, has been found to regulate the host immune response in Chagas 106 
disease patients by decreasing IFN-γ and the percentage of necrotic cells in the peripheral blood 107 
mononuclear cell (PBMC) pool, and reducing the rate of T. cruzi antigen-stimulated PBMC 108 
proliferation in cultured cells (17). The source and relevance of resolvins to T cruzi infection is 109 
currently uninvestigated. 110 
The full complement of the T. cruzi lipidome is yet to be determined.  We asked whether T. cruzi 111 
infection resulted in up regulation of SPM expression and whether there were contributions to 112 
the pro-resolution pathway from both host and parasite. We hypothesized that infection with T. 113 
cruzi results in an increased expression of resolvins both in vitro and in vivo.  Indeed, herein we 114 
demonstrate that mice infected with T. cruzi display increased levels of resolvin D1 (RvD1) and 115 
that the trypomastigote form of the parasite contains RvD1, RvD5 and RvE2. Thus, it is of 116 
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interest that T. cruzi synthetized both pro-inflammatory (TXA2) and SPM (resolvins) that are 117 
essential regulators of host response that promote transition to chronic infection. This 118 
observation may have new implications for the pathogenesis of Chagas disease.  119 
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Materials and Methods 120 
Animal Ethics Statement:  All animal experiment were performed with approval of the 121 
Institutional Animal Care and Use Committee of the Albert Einstein College of Medicine. 122 
Parasitology and Pathology:  The Brazil and Tulahuen strains of T. cruzi were maintained by 123 
serial passage in C3H mice (Jackson Laboratories, Bar Harbor, ME). For studies with the Brazil 124 
strain 8-week old male CD-1 mice were infected with 5x10
4
 parasites. Parasitemia was 125 
determined by counting in an hemocytometer chamber as previously described (18).  126 
Trypomastigotes of both the Brazil and Tulahuen strains of T. cruzi were propagated in a 127 
myoblast cell line (L6E9) as previously described(19). The RH strain of Toxoplasma gondii was 128 
maintained in cultured human foreskin fibroblasts.  The T. brucei brucei Lister 427 strain was 129 
provided to us by Dr. George Cross (The Rockefeller University, New York, NY). Hearts were 130 
fixed in 10% (v/v) neutral buffered formalin and sections (5 m) were stained with Hematoxylin 131 
and Eosin (H&E). 132 
Cardiac Magnetic Resonance Imaging (MRI): For magnetic resonance imaging (MRI), mice 133 
were anesthetized with isoflurane inhalation (2% (v/v) in medical air administered via a nose 134 
cone).  MRI compatible electrocardiogram (ECG) electrodes were inserted in the left front and 135 
right rear paws and the ECG signal was used as a trigger signal with a Small Animal Instruments 136 
physiological monitoring system (Stony Brook, NY). Mice were positioned in a 35-mm ID 1H 137 
volume coil [Molecules2Man Imaging Co., Cleveland, OH(20)]. Body temperature was 138 
maintained at 34∼35°C using warm air with feedback from a body surface thermocouple and a 139 
small respiratory sensor balloon, taped onto the abdomen, provided for respiratory gating. 140 
Images were acquired using a 9.4 T Varian Direct Drive animal magnetic resonance imaging and 141 
spectroscopic system (Agilent Technologies, Inc. Santa Clara, CA). One mm thick slices were 142 
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acquired in short-axis orientation using an ECG-triggered and respiratory gated multi-frame 143 
tagged cine sequence. The imaging parameters used were field of view (FOV) of 40×40 mm
2
, 144 
matrix size of 256×256, TE of 2.6 ms, TR of 5.5 ms, flip angle of 25°, number of averages of 2. 145 
General considerations regarding ELISA and  LC-MS/MS assays:  T. cruzi epimastigotes 146 
were cultured in LIT medium which we have assayed and contains no resolvins (by both ELISA 147 
and LC-MS-MS). They were washed 3 times in PBS (containing no resolvins) and lysates were 148 
made from these epimastigotes. Trypomastigotes of T. cruzi were obtained from infected 149 
myoblast cultures which we confirmed contained no resolvins (by both ELISA and LC-MS-MS). 150 
Lysates of T. brucei trypomastigotes and tachyzoites of the RH strain of Toxoplasma gondii 151 
prepared in similar fashion contained no resolvins indicating the resolvin content of T. cruzi was 152 
not an artifact of culture conditions. Positive controls for the LC-MS/MS were the known 153 
authentic standards for the resolvins. Negative controls were the L6E9 myoblasts which we found 154 
to have no detectable amounts of resolvins. The limits of detection of this LC-MS-MS system ~ 155 
10-15 picomoles. Resolvin (Rv)D1 was determined in lysates of 1x10
6 
trypomastigote of both 156 
the Tulahuen and Brazil strains of T. cruzi and trypomastigotes of T.b. brucei according to 157 
manufacturer's specifications (Cayman Chemical Company, Ann Arbor, MI, USA). Blood was 158 
collected from infected CD-1 mice by retro-orbital bleed, centrifuged and frozen at −80°C until 159 
use. RvD1 levels for all experiments were determined according to absorbance measured 160 
between 405 - 420 nm via a microplate reader.  161 
Lipid mediator (LM) metabololipidomics:  LM metabololipidomics was performed as 162 
described (Colas et al, 2014). After hypotonic lysis, parasites were further sonicated and snap 163 
frozen (stored at -80C until analyzed). Briefly, parasite lysates were placed in ice-cold methanol 164 
(containing deuterium labeled internal standard (d5-RVD2, d4-PGE2, d5-LXA4 and d4-LTB4, 165 
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500pg each) to facilitate quantification and recovery. Samples were held at -20C for 45 minutes 166 
to allow protein precipitation and centrifuged. Supernatants were collected and placed onto an 167 
automated extraction system (Biotage) using a C18 column. Bioactive LMs were collected and 168 
injected into an LC system (Shimadzu) coupled to a Qtrap 5500 (ABSciex). Identification was 169 
conducted using published criteria including matching retention time to synthetic standards and a 170 
minimum of 6 diagnostic ions in the MS-MS mode as reported (21). 171 
Statistical analysis:  All other data are expressed as the mean (±SEM) and were analyzed using 172 
GraphPad Prism statistics software (GraphPad Software Inc., San Diego, CA). For analysis of 173 
differences between groups the Student’s t test was performed. A level of significance of 5% was 174 
chosen to denote differences between means.  175 
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Animal studies 177 
Parasitology, Pathology and Cardiac Imaging 178 
Parasitemia was first detected at 15 days post infection (dpi), peaked at 4-5x10
5
 179 
trypomastigotes/ml at 35 to 40 dpi and waned by 60 dpi when parasitemia was undetectable 180 
(Figure 1A). Mortality was 50% during acute infection (Figure 1B).  At 100 dpi cardiac imaging 181 
demonstrated an enlarged heart and a significant increase in the right ventricular internal 182 
diameter consistent with previous reports (20) (Figure 1C and D). Histopathological examination 183 
of the heart during the acute phase revealed myonecrosis and parasite pseudocysts (Figure 1E). 184 
During the chronic phase there was cardiac myocyte hypertrophy, chronic inflammation and 185 
fibrosis, consistent with previous reports (6). 186 
 187 
Plasma Resolvin D1 increases during acute T. cruzi infection 188 
There was a rapid rise in RvD1 (g/ml of plasma) in infected mice that was evident at 20 dpi and 189 
remained elevated out to 140 dpi during the chronic phase of infection (Figure 2A). This profile 190 
suggests that RvD1 is derived both from parasite and host.  To assess this hypothesis we 191 
examined RvD1 levels in parasite lysates.  192 
 193 
Resolvin D1 levels in parasite extracts as determined by ELISA 194 
Trypomastigotes of both the Brazil and Tulahuen strains of T. cruzi had significantly greater 195 
amounts of RvD1 compared to epimastigotes of the Tulahuen (Figure 2B) and Brazil (data not 196 
shown) strains. RvD1 was not detected at significant levels in trypomastigotes of T. brucei, 197 
tachyzoites of T. gondii or from uninfected L6E9 myoblasts. In contrast, myoblasts infected with 198 
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the Tulahuen strain of T. cruzi (which contained intracellular amastigotes) produced significant 199 
amounts of RvD1 compared to uninfected myoblasts.  Although production was lower than in 200 
free trypomastigotes these data suggest that intracellular amastigotes synthesize RvD1 or that 201 
infection stimulates production by myoblasts. To unequivocally determine that RvD1 was being 202 
produced we performed LC-MS-MS analysis, the gold standard for identification of bioactive 203 
lipid mediators. 204 
 205 
LM metabololipidomics 206 
The above results clearly indicated that RvD1 is present in trypomastigotes of T. cruzi. Figure 3 207 
demonstrates the characteristics LC-MS-MS spectra used for the identification of RvD1, RvD5 208 
and RvE2 in parasite extracts. The resulting lipidomic profiles are representative of 3 separate 209 
parasite lysates from both Tulahuen and Brazil strains.  Extracts of uninfected L6E9 myoblasts 210 
and LIT media were negative for lipid species suggesting all identified species were parasite 211 
derived (data not shown). Both strains had the precursor lipids docosahexenoic acid (DHA), 212 
eicosapentaenoic acid (EPA) and arachidonic acid (Table 1) indicating that biosynythesis of all 213 
pro-inflammatory and pro-resolving mediators were possible.  DHA and its bioactive 214 
metabolome were present in significantly higher quantities indicating a potential preference for 215 
biosynthesis of mediators derived from this fatty acid.  Consistent with earlier reports from our 216 
laboratory and others(8) we identified the arachidonic acid metabolites PGE2, PGD2 and PGF2 217 
in T. cruzi lysates (Table 2).  The presence of 5/12/15-HETE and 5/12/15/18-HEPE in extracts 218 
(Table 3) suggests active lipoxygenase pathways are present in the parasite with arachidonic acid 219 
and EPA as the respective precursor FFAs(22).  Potential downstream pro-inflammatory end 220 
products might also include leukotrienes; however, no leukotriene B4 production was identified 221 
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(Table 3).  Thus, the primary class of pro-inflammatory lipid species produced by T. cruzi is 222 
prostaglandins. 223 
 224 
An active lipoxygenase pathway would also initiate and promote the biosynthesis of pro-225 
resolving lipid mediators such as lipoxins, resolvins, maresins and protectins.  When we 226 
examined lysates by LC-MS-MS no evidence of lipoxins, protectins or maresins were observed 227 
(Table 4).  However, their pathway markers were identified indicating that trypomastigotes of T. 228 
cruzi have the enzymatic capability to produce these mediators. Of interest, RvD1 and RvD5 229 
were biosynthesized by both the Tulahuen and Brazil strains of T. cruzi (Table 4).  Moreover, the 230 
Brazil strain produced significant levels of RvE2 (Table 4) indicating that only the Brazil strain 231 
utilized EPA to produce pro-resolving mediators.  The precursor of RvE2 (18-HEPE) is lower in 232 
the Brazil strain perhaps reflecting increased use of this precursor for RvE2 synthesis.  These 233 
studies clearly indicate that RvD1 is present in trypomastigotes of T. cruzi and that D and E 234 
series resolvins are the likely primary lipid mediators through which T. cruzi dampen the host 235 
response to infection. 236 
  237 
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The heart is an important focus of infection by T. cruzi, although other tissues and organs are 239 
infected as well. Acute T. cruzi infection is characterized by an upregulation of pro-inflammatory 240 
cytokines and chemokines and an influx of inflammatory cells. In the setting of Chagas disease, 241 
as in other disease states, the acute inflammatory response is a “double-edged" sword, in that, it 242 
is needed to control the infection, but also leads to tissue injury. The chronic phase of Chagas 243 
disease is accompanied by the appearance of chronic inflammatory cells and cardiac remodeling 244 
(i.e., fibrosis). The present study clearly demonstrates, for the first time, that T. cruzi 245 
trypomastigotes and amastigotes produce RvD1 which likely contributes to the resolution of 246 
inflammation. This was confirmed by both ELISA and LM metabolomic profiling. In addition, 247 
T. cruzi-infected mice display elevated circulating RvD1 levels during the acute phase of 248 
infection and well into the chronic phase when peripheral parasitemia has waned and, in the 249 
mouse model, cardiomyopathy is present. Lysates of trypomastigotes of the Brazil and Tulahuen 250 
strains contained RvD5 while trypomastigotes of the Brazil strain contained RvE2.  We did not 251 
identify RvD1 in a variety of other protozoan parasites (T. gondii and T. brucei) and non-infected 252 
mammalian cells. 253 
Historically, the resolution of inflammation was considered a passive process resulting from the 254 
loss or dilution of pro-inflammatory mediators from the extracellular milieu. It is now 255 
understood, however, that the resolution of inflammation is instead, an active and programmed 256 
event (13).  The mediators of the resolution of inflammation, SPM (include the resolvins, 257 
protectins and maresins), are produced enzymatically from essential fatty acids (EFA). RvD1 is 258 
one of these bioactive mediators and as noted in E. coli-induced peritonitis, RvD1 reduces 259 
bacterial titers and hypothermia, increases survival and enhances microbial containment and 260 
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killing by phagocytic cells (16). RvD5 has also been shown to be involved in the setting of 261 
experimental E. coli by enhancing phagocytosis. Combination of RvD5 with the antibiotic 262 
ciprofloxacin was able to accelerate the antibiotic effect and the same was observed in the setting 263 
of experimental Staphylococcal infection (16). RvE2, identified by LM metabololipidomics, has 264 
potent leukocyte-directed actions that regulates chemotaxis of human neutrophils, enhancing 265 
phagocytosis and anti-inflammatory cytokine production. RvE2 rapidly down-regulates surface 266 
expression of human leukocyte integrins in whole blood and dampened responses to platelet-267 
activating factor. These actions appear to be mediated by leukocyte G-protein-coupled receptors.  268 
Collectively, these observations indicate that RvE2 can stimulate host-protective actions 269 
throughout initiation and resolution in the innate inflammatory responses (23). 270 
The ability of the parasite and host to liberate pro-resolving mediators is likely to alter the course 271 
of disease.  The identification of 15- and 5(S),15 (S)-HETE in T cruzi extracts suggests 15-LO 272 
activity (which has been previously reported in parasites such as T. gondii)(24), however, this 273 
has not been previously documented and no data is available comparing disease progression in 274 
15LO
-/-
 mice or with pharmacological antagonists of 15LO activity.  Conversely, a comparison 275 
of 5LO activity has been performed (25).  5LO activity is essential for synthesis of many pro-276 
resolving mediators (such as E-series resolvins and lipoxins).  Direct comparison of 5-LO null 277 
mice (intact parasite RvD1 synthesis) and infected mice treated with NDGA (1.25 278 
mg/mouse/day), a 5LO inhibitor (inhibiting both mouse and parasite RvD1) indicated that 279 
NDGA treatment promoted earlier development of parasitemia and greater lethality than the 5LO 280 
null mice (25) although number of cardiac amastigote nests and anti-oxidant protection were 281 
similar. These differences suggest that NDGA may have inhibited parasite- and host-derived 282 
5LO activity and that parasite 5LO derivatives may play a significant role in suppressing early 283 
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parasite growth during acute infection and promote survival of the host through the acute 284 
infection.  Our data suggest that of the available mediators only RvE2 production would be 285 
affected by such a difference (as no lipoxin nor leukotriene production was observed in the T. 286 
cruzi strains tested). These data indicate the liberation of SPMs from the parasite may be 287 
important in mediating the transition from acute to chronic disease and promoting host survival 288 
during experimental T. cruzi infection. 289 
Earlier, our groups reported that T. cruzi synthesizes the lipid mediators TXA2 and PGF2α(7), 290 
TXA2 is both a potent vasoconstrictor and a pro-inflammatory mediator synthesized by both 291 
trypomastigotes and amastigotes (7, 22). The majority of TXA2 in the serum of infected mice is 292 
derived from the parasite (7). In the present report, we have demonstrated that trypomastigotes 293 
and amastigotes of both the Brazil and Tulahuen strains of T. cruzi strains contain RvD1, RvD5 294 
and RvE2, important pro-resolving mediators. Plasma RvD1 levels are elevated in T. cruzi 295 
(Brazil strain) infected mice and it is possible that the source of the RvD1 is, in part, from the 296 
parasite itself.  The synthesis of pro-inflammatory and pro-resolving lipid mediators suggests 297 
that the parasite is able to modulate its microenvironment through these metabolites.  If the net 298 
result is a damping down of the inflammatory response, this may be important in the 299 
perpetuation of the infection into the chronic phase. There are other anti-inflammatory factors 300 
present during T. cruzi such as interleukin-10. In that regard, it was recently demonstrated that 301 
there is an interaction between RvD1 and interleukin-10 in the resolution of inflammation in 302 
adipose tissue in the experimental obese state (26).  These observations suggest that the addition 303 
of such an anti-parasitic regimen may ameliorate some of the consequences of this infection. 304 
Resolvins dampen the inflammatory response and promote resolution of infections, which 305 
prevents fibrosis, and enables parasite persistence and the perpetuation of the parasite life cycle 306 
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The biosynthesis of lipid mediators by T. cruzi is increasingly complex but may provide 308 
advantages for longevity of infection.  The parasite genome encodes terminal synthases for some 309 
eicosanoid species and the ability of T. cruzi to elevate the host plasma levels of lipid mediators 310 
in mice knocked out for the respective terminal synthase (such as the TXA2 synthase null mice) 311 
suggest these pathways are active during disease (7).  While T. cruzi proteins such as PGF2α 312 
synthase are highly homologous to other prokaryotic enzymes (such as yeast old yellow enzyme 313 
(TcOYE) and T. brucei synthase (TbPGFS))(28-30) their primary sequences bare significant 314 
differences to mammalian terminal enzymes (29, 30).  Moreover, the T. cruzi enzymes are 315 
resistant to pharmacological inhibitors of mammalian terminal synthases indicating that the 316 
active sites are also topographically or structurally different (28).  Thus, parasite-derived 317 
eicosanoids manipulate host responses during infection but are intractable to current therapies. 318 
Most interestingly, the terminal synthase for the primary T. cruzi prostaonoid TXA2 has eluded 319 
genomic efforts to identify it prompting suggestions that the parasite may co-opt host synthetic 320 
pathways by the process of trogocytosis (31).  Similarly, the 15LO and 5LO activities needed for 321 
D and E series resolvin biosynthesis are not predicted from the T. cruzi genome.  It therefore 322 
remains to be determined whether the biosynthetic pathways exist in T. cruzi or are 323 
serendipitously stolen from infected host cells.  Only the examination of chronically infected null 324 
mice, once parasite numbers have declined, is likely to yield these answers. 325 
Previously, we reported that T. cruzi produces the pro-inflammatory and pro-thrombotic lipid 326 
TXA2. Herein we now demonstrate that this parasite also produces several pro-resolving lipids. 327 
Taken together, this parasite may be able to modulate its microenvironment and enhance 328 
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persistence. On the other hand, the administration of RvD1 may ameliorate the inflammation and 329 
fibrosis in the heart. These experiments are currently underway.  330 
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FFA Precursor   
Trypomastigotes of  T. cruzi strains 
(range, pg/mg protein) 
Species Q1 Q3 Tulahuen Brazil 
EPA 301 257 1.6---1194^ 2.9---1937^ 
          
DHA 327 283 113---15111^ 62.1---3841^ 
4S,14S‐diHDHA 359 221 * * 
17-HDHA 343 245 9.7---199.3 6.4---242.4 
14-HDHA 343 205 15.7---86.8 14.9-‐141.6 
7-HDHA 343 141 16.9-‐262.4 11.3---88.2 
4-HDHA 343 101 94.5---427.4 70.0-‐471.3 
          
AA 303 259 15.5---2529^ 32---5766^ 
 422 
Table 1:  Quantitation of free fatty acid (FFA) precursors in lysates of trypomastigotes by 423 
LC-MS/MS.  Expression of lipid species are quantified from peak height and expressed a pg/mg 424 
protein.  Data represent the range of samples documented from 3 independent lysates for each 425 
strain.  * represents samples with values below the detection limit, ^ = samples are in ng/mg 426 
protein. EPA,; DHA,; HDHA, hydroxy Docosahexaenoic Acid; AA, .arachidonic acid 427 
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Prostaglandin   
Trypomastigotes  of T. cruzi  strains (range, 
pg/mg protein) 
Lipid Species Q1 Q3 Tulahuen strain Brazil strain 
PGD2 351 189 1.4-3.9 2.7-23 
PGE2 351 189 2.0-21.4 6.0-48.6 
PGF2α 353 193 2.6-38.9 2.7-2.6 
 429 
Table 2:  Quantitation of prostaglandin species in lysates of trypomastigotes of T. cruzi by 430 
LC-MS/MS.  Expression of lipid species are quantified from peak height and expressed a pg/mg 431 
protein.  Data represent the range of samples documented from 3 independent lysates for each 432 
strain. PG, prostaglandin. 433 
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Lipoxygenase-derived    
Trypomastigotes of T. cruzi strains (range, 
pg/mg protein) 
Lipid Species Q1 Q3 Tulahuen strain Brazil strain 
LTB4 335 195 * * 
20-OH-LTB4 351 195 * * 






5‐HETE 319 115 54.6-101.6 26.3-122.1 
12-HETE 319 179 11.1-46.9 15.3-143.3 
15-HETE 319 219 24.8-166.4 39.7-328.1 
5S,15S-diHETE 335 235 2.3-5.2 5.7-8.0 
          
5-HEPE 317 115 5.4-12.9 2.5-31.0 
12-HEPE 317 179 0.7-6.1 0.6-1.0 
15-HEPE 317 219 2.5-3.3 2.3-3.4 
18-HEPE 317 259 3.8-5.4 1.7-2.2 
5S,15S-diHEPE 333 115 1.3-27.7 1.7-13.6 
Table 3:  Quantitation of lipoxgenase-derived lipid species in lysates of T. cruzi 435 
trypomastigotes by LC-MS/MS.  Expression of lipid species are quantified from peak height 436 
and expressed a pg/mg protein.  Data represent the range of samples documented from 3 437 
independent lysates for each strain.  * represents samples with values below the detection limit.  438 
LT, leukotriene; HETE,; hydroxy-eicosatetraenoic acid; diHETE, di-hydroxy-eicosatetraenoic 439 
acid; HEPE, hydroxy-eicosapentaenoic acid; diHEPE, di-hydroxy- eicosapentaenoic acid  440 
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Pro-Resolving   
Trypomastigotes of T .cruzi  (range, 
pg/mg protein) 
Lipid Species  Q1 Q3 Tulahuen strain Brazil strain 
RvD1 375 141 1.2-1.4 1.8-7.0 
RvD2 375 215 * * 
RvD3 375 147 * * 
RvD5 359 199 1.4-1.6 0.7-1.9 
RvD6 359 159 * * 
          
RvE1 349 161 * * 
RvE2 333 253 * 9.5-23.6 
RvE3 333 201 * * 
          
PD1 359 153 * * 
22-OH-PD1 375 153 * * 
22-COOH-PD1 389 153 * * 
          
MaR1 359 250 * * 
          
LXA4 351 115 * * 
LXB4 351 115 * * 
LXA5 349 215 * * 
LXB5 349 221 * * 
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Table 4:  Quantitation of pro-resolving lipid mediators in lysates of trypomastigotes of T. 441 
cruzi by LC-MS/MS.  Expression of lipid species are quantified from peak height and expressed 442 
a pg/mg protein.  Data represent the range of samples documented from 3 independent lysates for 443 
each strain.  444 
* represents samples with values below the detection limit. RvD, resolvins derived from 445 
docosahexenoic acid; RvE, resolvins derived from eicosapentaenoic acid; PD, protectin; MaR, 446 
maresin; LX, lipoxin. 447 
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Figure 1. Kinetics of cardiomyopathy in T. cruzi infection.  Parasitemia (A) and mortality (B) 450 
in CD-1 mice infected with 5x10
4
 trypomastigotes of the Brazil strain of T. cruzi. C-D. 451 
Representative cardiac MRI of control (C) and infected (D) mouse heart revealing an enlarged 452 
right ventricle. E-F. Representative histopathology of the heart during the acute and chronic 453 
infection showing pseudocysts of amastigotes () and inflammation. Images are representative 454 
of n=5 mice in each group.   455 
Figure 2.  T-cruzi are a source of RvD1 during infection. A.  Serum RvD1 levels in mice 456 
inoculated with 5x10
4 
Brazil strain trypomastigotes.  Data are meanSD (n=5).  ** represents 457 
significance (p≤0.05) from uninfected mice.  B.  Release of RvD1 from T cruzi, related protists, 458 
and infected L6E9 cells.  RvD1 release was measured by ELISA (pg/mL) from conditioned 459 
media.  Data are meanSD (n=3). ** represents significance (p≤0.05) from epimastigotes and 460 
uninfected L6E9 cells.  epis= epimastigotes forms of Tulahuen strain, trypos=trypomastigotes of 461 
the Brazil and Tulahuen strains, Toxo= lysates of the RH strain of Toxoplasma gondii, T. 462 
brucei= Trypanosma. brucei.  L6E9 myoblasts infected (Inf) or uninfected (Uninf) with 463 
trypomastigotes of the Tulahuen strain of T. cruzi. 464 
Figure 3. Representative spectra used to identify lipid mediators of the resolving class.  LC- 465 
MS-MS fragmentation spectra employed for the identification of RvD1, RvD5 and RVE2 in 466 
lysates of trypomastigotes of T. cruzi from Brazil and Tulahuen strains. 467 
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